Osborne Clarke has advised Bone Therapeutics on its acquisition of a majority shareholding in Medsenic

International legal practice Osborne Clarke has advised Bone Therapeutics on its acquisition of a majority stake in Medsenic. This combination of Bone Therapeutics and Medsenic has created a new biopharma company, BioSenic.

The combination of the two companies will significantly delineate and expand Bone Therapeutics' therapeutic portfolio, which targets a broad range of inflammatory and orthopaedic indications. The two companies are currently conducting several mid- to late-stage clinical trials in lupus, chronic graft-versus-host disease, tibial fractures and other indications.

Bone Therapeutics said in a statement:

Combining these clinical development programmes within a single entity would therefore offer a number of economic, financial and operational benefits and synergies"

This transaction demonstrates Osborne Clarke's capacity to advise on complex ECM M&A transactions. The Belgian team was led by partner Hadrien Chef and included partner David Haex and the following associates: Violette Keppenne, Tonya Aelbrecht, Laurent De Pauw and Shahine Kalantari. They worked in collaboration with Osborne Clarke in Paris with partner Catherine Olive and associate Cyrille d'Amécourt.